secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLIANT THERAPEUTICS, INC. (PLRX)
CIK:        0001746473
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0001746473-24-000041
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pliant Therapeutics reports Q4 2023 net loss of $41.1M; positive bexotegrast data in PSC
--------------------------------------------------------------------------------

- Net loss $41.1M vs $35.1M YoY; R&D expenses $33.2M (+32% YoY) driven by bexotegrast costs.
- Cash $495.7M; expected to fund operations into H2 2026.
- Positive 12-week data from 320 mg cohort of INTEGRIS-PSC: reduced ELF and PRO-C3, improved bile flow.
- BEACON-IPF Phase 2b enrolling ~270 patients; 24-week PSC data expected mid-2024.
- PLN-101095 Phase 1 solid tumors enrolling third cohort; DMD regulatory filing expected Q1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746473/000174647324000041/0001746473-24-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746473/000174647324000041/plrx-20240227.htm
  HTML page:      https://secwatch.observer/filing/0001746473-24-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer